

OX40/TNFRSF4 Protein, Rhesus, Recombinant (His)

General Information

Synonyms:	tumor necrosis factor receptor superfamily, member 4
Protein Construction:	A DNA sequence encoding the rhesus TNFRSF4 (XP_001090870.1) (Met1-Ala216) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Leu 29
Species:	Rhesus
Expression Host:	HEK293 Cells
Accession:	A0A5F7ZEC3
Molecular Weight:	21.7 kDa (predicted); 42.4 kDa (reducing conditions)

QC Testing

Biological Activity:	1.Immobilized Recombinant Rhesus OX40/TNFRSF4 Protein (His Tag) (Cat#TMPY-04723) at 1 µg/mL (100 µL/well) can bind Anti-OX40 (Vonlerolizumab Biosimilar), the EC50 is 2.8 ng/mL (Routinely tested). 2.Immobilized Recombinant Rhesus OX40/TNFRSF4 Protein (His Tag) (Cat#TMPY-04723) at 2 µg/mL (100 µL/well) can bind Recombinant Human OX40 Ligand/TNFSF4 Protein (hFc Tag) (Cat#TMPY-04832), the EC50 is 2-10 ng/mL (QC tested).
Purity:	> 95 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a

reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease. Cancer Immunotherapy Co-stimulatory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: WB Antibodies Immune Checkpoint Proteins Immune Checkpoint Targets Immunotherapy Targeted Therapy

Reference

- Compaan D.M., et al. (2006) . The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321-1330.
- Kawamata S., et al. (1998). Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 273:5808-5814.
- Byun M., (2013) Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J. Exp. Med. 210:1743-1759.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481